Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable of reaching targets beyond the liver. The Japanese drugmaker is best ...

Milliardenschwere Investitionen in Deutschland haben zudem Daiichi-Sankyo aus Japan und der Schweizer Pharmariese Roche verkündet. mit Dpa/jel ...

So baue der US-Pharma-Konzern Eli Lilly in Rheinland-Pfalz für 2,3 Milliarden Euro ein neues Werk und die Pharmaunternehmen Roche aus der Schweiz sowie Daiichi-Sankyo aus Japan investierten ...

Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the DESTINY-Gastric04 Phase III trial, regarding the primary endpoint of ...

Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced non ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a randomized clinical trial in second-line metastatic stomach cancer ...

Milliardenschwere Investitionen in Deutschland hatten zudem auch Daiichi-Sankyo, Roche und Merck beschlossen. Die Investitionen aus dem Ausland machen Hoffnung, dass Deutschland als Standort ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday. December 24 ...

AstraZeneca and Daiichi Sankyo have claimed FDA approval for a second antibody-drug conjugate (ADC) for breast cancer, hoping to build on the success of a partnership that already spawned a ...

A health ministry panel of experts on July 31 endorsed the plan for Daiichi Sankyo Co. to begin producing and distributing the vaccine, which creates immunity for the conventional strain of the virus.